A Multicenter Randomized Double-Masked Study Comparing Preservative-free Brimonidine Tartrate Ophthalmic Solution 0.025% with LUMIFY® 0.025% for Ocular Redness in Adults

Abstract Introduction Ocular redness is common, can affect quality of life, and can be relieved by short-term use of topical adrenergic receptor (AR) agonists. Brimonidine tartrate ophthalmic solution 0.025% (LUMIFY® 0.025%) is the first α2-AR-selective agonist approved for ocular redness. The prese...

وصف كامل

التفاصيل البيبلوغرافية
الحاوية / القاعدة:Ophthalmology and Therapy
المؤلفون الرئيسيون: Melissa Toyos, Melinda DiVito, Elisabeth M. Messmer, Selina McGee, Jared Peterson, Assem Patel, Guruprasad Pattar, David G. Evans, Patrick M. Vollmer, Gina Wesley
التنسيق: مقال
اللغة:الإنجليزية
منشور في: Adis, Springer Healthcare 2025-07-01
الموضوعات:
Brimonidine
Benzalkonium chloride
Brimonidine tartrate ophthalmic solution 0.025%
Hyperemia
LUMIFY
Ocular redness
الوصول للمادة أونلاين:https://doi.org/10.1007/s40123-025-01194-z

الانترنت

https://doi.org/10.1007/s40123-025-01194-z

مواد مشابهة